Huntington's review finds support for a marker before motor diagnosis
Neurofilament light met the authors' evidence criteria as a prognostic marker, but inconsistent reporting limits the wider biomarker literature.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This review asked whether markers in body fluids can help track Huntington's disease across its stages. The authors judged neurofilament light, or NfL, sufficiently supported as a prognostic marker before clinical motor diagnosis. That concerns anticipating disease progression; the abstract does not establish that testing this marker improves treatment decisions or patient outcomes.
The review identifies inconsistent reporting, difficulty comparing results and concerns about study rigor. This abstract-only account also lacks test accuracy estimates and individual follow-up details needed to judge practical usefulness.
Results depend on disease stage
The authors also found statistically significant pooled results for other markers at early and later disease stages. However, the abstract does not give effect sizes, comparison groups or thresholds that would make a test result interpretable.
What the review supports
The review pooled studies with reproducible findings and found support for validating fluid markers across disease stages. It also identified gaps in reporting and research rigor that complicate comparisons between study outcomes.
The original publication
Systematic Review with Meta-Analysis of Biofluid Markers for Huntington's Disease.
Paulsen JS, Bovin NA, Clemsen JD et al.
Mov Disord · 2025
- PubMed ID
- 41081429
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.